AlloVir (ALVR) Investor Presentation - Slideshow

AlloVir Key Investment Highlights - Posoleucel has franchise potential in stem cell (allo-HCT) and solid organ transplant (SOT) patients[5] - AlloVir has $234 million cash as of December 31, 2022[5] Posoleucel Clinical Trials and Data - Three ongoing global Phase 3 registrational trials for three first-to-market indications are expected to complete enrollment in 2023[5] - Topline Phase 2 data in kidney transplant is expected in Q1 2023[5] - Phase 2 CHARMS Treatment Study Demonstrated 93% Efficacy In Treatment-Refractory Patients[40] - 23 out of 26 (88%) patients CSI-free through Week 14 in Phase 2 Prevention Study[33] - 22 out of 26 (85%) patients reactivated ≥1 target virus in Phase 2 Prevention Study[33] Posoleucel Market Opportunity - Posoleucel has a potential >$1 billion commercial opportunity in Allo-HCT alone[65] - Multi-virus infections are common in allo-HCT patients and contribute to significant mortality, with 61% of patients treated with antiviral therapies within the first 100 days[23] Pipeline and Platform - The VST platform minimizes antigen competition, enabling retention of VST diversity and polyclonality[9] - Rationally designed cell bank, facilitating availability of VSTs covering >95% of patients[9]